Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - yellow fever virus, quantity: 1000 pfu e.1000 mouse ld50 - injection, powder for - excipient ingredients: calcium chloride dihydrate; magnesium sulfate heptahydrate; histidine hydrochloride; sodium chloride; dibasic sodium phosphate dihydrate; alanine; sorbitol; potassium chloride; lactose monohydrate; monobasic potassium phosphate; sodium hydroxide - prevention of yellow fever. vaccination is recommended for:,? every individual aged 9 months and over living or travelling through an endemic area with a current or periodic risk of yellow fever transmission. ? non-vaccinated individual moving from an endemic area with a current or periodic risk of yellow fever transmission to a potentially receptive non-endemic area with a current or periodic risk of yellow fever transmission. ? laboratory workers handling potentially infectious materials. in order to be officially recognised, the yellow fever vaccination must be administered in an approved vaccination centre and registered on an international certificate. the validity period of the certificate is established according to international health regulations recommendations and starts 10 days after primary vaccination and immediately after re-vaccination.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - yellow fever virus -

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - yellow fever vaccine 1000 [iu] (17d strain);   - suspension for injection - 1000 iu - active: yellow fever vaccine 1000 [iu] (17d strain)   excipient: alanine calcium chloride dihydrate dibasic sodium phosphate dihydrate histidine hydrochloride lactose monohydrate magnesium sulfate heptahydrate monobasic potassium phosphate potassium chloride sodium chloride sodium hydroxide sorbitol purified water sodium chloride - prevention of yellow fever. vaccination is recommended for: · every person over 9 months of age living or travelling through an endemic area. · non-vaccinated persons moving from an endemic to a potentially receptive non-endemic area. · laboratory workers handling potentially infectious materials. · in order to be officially recognised, the yellow fever vaccination must be administered in an approved vaccination centre and registered on an international certificate. the validity period of the certificate is established according to international health regulations recommendations and starts 10 days after primary vaccination and immediately after re-vaccination.

Israel - English - Ministry of Health

sanofi israel ltd - yellow fever virus strain 17d204 (substrain ab237) - powder and solvent for suspension for injection - yellow fever virus strain 17d204 (substrain ab237) - yellow fever, live attenuated - stamaril is indicated for active immunization against yellow fever in persons:• travelling to, passing through or living in an endemic area,• travelling to any country that requires an international certificate of vaccination for entry(which may or may not depend on the previous itinerary).• handling potentially infectious materials (e.g. laboratory personnel).see sections 4.2, 4.3 and 4.4 regarding the minimum age for vaccination of children under special circumstances and guidance for vaccination of other specific patient populations.in order to comply with vaccine regulations and to be officially recognized, yellow fever vaccines must be administered in an approved world health organization (who) vaccination centre and registered on an international certificate of vaccination. the validity period of thiscertificate is established according to international health regulations (ihr) recommendations, and starts 10 days after primary vaccination and immediately after re-vaccination (see section 4.2).

Ireland - English - HPRA (Health Products Regulatory Authority)

sanofi pasteur msd ltd - yellow fever virus 17 d-204 strain - suspension for injection - 1000 - yellow fever vaccines

Malta - English - Medicines Authority

sanofi pasteur 14 espace henry vallée , 69007 lyon, france - yellow fever, virus strain, d - powder and solvent for suspension for injection - yellow fever virus strain 17d 1000 iu - vaccines

Ireland - English - HPRA (Health Products Regulatory Authority)

sanofi pasteur - yellow fever virus 17 d-204 strain - powder and solvent for suspension for injection in pre-filled syringe - 1000 international unit(s) - yellow fever vaccines; yellow fever, live attenuated

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

sanofi - yellow fever virus strain 17d - powder and solvent for suspension for injection

United States - English - NLM (National Library of Medicine)

sanofi pasteur inc. - yellow fever virus strain 17d-204 live antigen (unii: py4eet359t) (yellow fever virus strain 17d-204 live antigen - unii:py4eet359t) - yellow fever virus strain 17d-204 live antigen 1000 [iu] in 0.5 ml